Neurobo pharmaceuticals, inc. (GEMP)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16
Operating activities
Net loss

-22,241

-21,312

-13,807

-16,456

-20,214

-23,637

-26,727

-29,319

-33,143

-33,415

-33,883

-29,090

-19,979

-14,586

0

0

0

Adjustments to reconcile net loss to net cash used in operating activities:
Stock-based compensation

-196

118

1,927

3,113

3,584

4,131

4,294

3,403

5,457

5,273

5,468

5,299

2,431

1,718

0

0

0

Non cash interest related to convertible notes - related party

-

-

-

-

-

-

-

-

-

-

-

-

-

145

0

0

0

Non cash interest related to convertible notes – related party

-

-

-

-

-

-

-

-

-

-

-

-

-

256

0

0

0

Non-cash discount amortization on convertible notes to related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

-17

0

0

0

Non-cash discount amortization on term loan

-

-

921

1,014

1,091

346

0

0

0

-

-

-

-

-

-

-

-

Revaluation of premium conversion derivative

-

-

-

-

-

-

-

-

-

-

-

-

-

850

0

0

0

Depreciation

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

lease liability principal payment

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Right-of-use leased asset depreciation

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Non-cash interest upon conversion of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

649

0

0

0

Change in assets and liabilities, net of the effects of the reverse asset acquisition:
Prepaid expenses and other assets

485

-824

-886

-411

257

196

172

233

-205

-198

-327

-301

-105

55

0

0

0

Accounts payable

401

-1,046

326

-901

-1,487

-1,981

-1,908

-905

-770

2,007

3,371

2,822

3,192

1,477

0

0

0

Accrued and other liabilities

1,914

966

-1,191

-615

-562

-574

-371

-810

123

-1,101

896

86

-995

496

0

0

0

Net cash used in operating activities

-8,007

-7,039

-10,938

-13,434

-17,845

-21,911

-24,558

-27,573

-27,914

-26,901

0

0

0

-

-

-

-

Investing activities
Purchases of property and equipment

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in investing activities

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-8,007

-7,039

-10,938

-13,434

-17,845

-21,911

-24,558

-27,573

-27,914

-26,901

0

0

0

-

-

-

-

Net cash used in operating activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Financing activities
Proceeds from issuance of convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

0

Proceeds from issuance of convertible notes to related parties

-

-

-

-

-

-

-

-

-

-

-

-

-

2,500

0

0

0

Repayment of principal

-

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Exercise of stock options

-

-

-

-

-

84

84

51

61

41

0

0

0

-

-

-

-

Exercise of stock options

0

-

-

-

-

25,150

25,150

25,150

25,150

12,541

0

0

0

-

-

-

-

Issuance costs

-

-

-

-

-

2,091

2,123

2,126

2,164

1,287

1,970

5,068

4,949

3,963

0

0

0

Net cash provided by financing activities

34,479

24,167

-10,998

-10,947

-11,091

22,392

23,024

33,121

33,093

21,341

0

0

0

-

-

-

-

Net decrease in cash and restricted cash

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net foreign exchange difference

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

Net increase (decrease) in cash and cash equivalents

-

-

-

-

-28,936

-

-

-

5,179

-5,560

-3,029

17,665

27,653

20,413

0

0

0

Supplemental disclosure of cash flow information:
Cash paid for interest

-

1

205

331

451

488

0

0

0

-

-

-

-

-

-

-

-

Supplemental non-cash financing transactions:
Net liabilities assumed in connection with the merger

-

-

-

-

-

-

-

-

0

-

0

0

0

-

-

0

0

Redemption value change of Series A preferred stock

-

-

-

-

-

-

-

-

-

-

-

-

-

366

0

0

0

Bifurcation of premium conversion derivative related to convertible notes

-

-

-

-

-

-

-

-

-

-

-

-

-

505

0

0

0